William Blair Starts ARS Pharmaceuticals Inc (SPRY) at Outperform

William Blair analyst Tim Lugo initiates coverage on ARS Pharmaceuticals Inc (NASDAQ: SPRY) with a Outperform rating.

The analyst comments "We are initiating coverage of ARS with an Outperform rating and estimate a fair value for shares of $17, based on a risk-adjusted net present value (NPV) for neffy for the treatment of type I hypersensitivity reactions, including anaphylaxis. With what we view as a significantly differentiated product, we believe ARS is positioned to become a major player in the market for self-administered epinephrine devices for the treatment of severe allergic reactions."

For an analyst ratings summary and ratings history on ARS Pharmaceuticals Inc click here. For more ratings news on ARS Pharmaceuticals Inc click here.

Shares of ARS Pharmaceuticals Inc closed at $8.53 yesterday.

You May Also Be Interested In

• Stifel Starts Arrowhead Pharma (ARWR) at Buy
• Q32 Bio Inc. (QTTB) PT Raised to $36 at Mizuho
• Diamondrock Hospitality (DRH) PT Raised to $12.50 at Stifel